Answers are grounded in this paper and cite their sources.
This first evaluation of the safety and efficacy of HER2-CAR T cells in patients with cancer shows the cells can persist for 6 weeks without evident toxicities, setting the stage for studies that combine HER2-CAR T cells with other immunomodulatory approaches to enhance their expansion and persistence.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: